Humana
HUM
$304.85
+3.22%
Humana Inc. is one of the largest private health insurers in the United States, specializing in government-sponsored healthcare programs such as Medicare, Medicaid, and the military's Tricare program. The company has established a distinct competitive identity as a leading pure-play Medicare Advantage insurer, complemented by its CenterWell segment which provides primary-care, at-home, and pharmacy benefit management services. The current investor narrative is dominated by the fallout from a severe fourth-quarter 2025 earnings miss, which triggered a dramatic stock price collapse, and the subsequent partial recovery driven by a favorable 2027 Medicare Advantage payment update from CMS in early April 2026. This has created a high-stakes debate around the sustainability of the company's margins and its ability to navigate regulatory and cost pressures in its core business.…
HUM
Humana
$304.85
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating: Hold. The core thesis is that while Humana presents a compelling deep-value opportunity after a 47% drawdown and a positive regulatory catalyst, the catastrophic Q4 fundamentals and lack of visible profit recovery warrant a cautious stance, making it a high-risk, high-potential-reward situation best suited for patient, risk-tolerant investors.
Supporting evidence includes an exceptionally low trailing PS ratio of 0.24, implying the stock is pricing in sustained distress. Revenue growth remains robust at 11.3% YoY, and analyst forward EPS estimates average $41.63, which if achieved, would imply a forward P/E of only ~5.6. The stock has shown powerful short-term momentum, up 32% in one month on the CMS news. However, these positives are counterbalanced by the severe Q4 net margin of -2.45%, negative free cash flow of -$1.85B, and a current ratio of 0.72 indicating liquidity stress.
The thesis would upgrade to a Buy if the company demonstrates a clear reversal in Q1 2026 results, with gross margins recovering above 14% and positive quarterly free cash flow generation. It would downgrade to a Sell if Q1 shows continued margin compression below 12% or if the stock fails to hold above the $200 support level, signaling a resumption of the downtrend. Valuation Verdict: The stock is deeply undervalued based on historical sales multiples and forward earnings estimates, but this discount is justified by the severe and recent profitability crisis. It is fairly valued only if one assumes a prolonged period of sub-par margins.
Sign up to view all
HUM 12-Month Price Forecast
Humana is at an inflection point, caught between a powerful valuation spring and a deeply damaged profit engine. The favorable CMS update provides a crucial lifeline, but the burden of proof is squarely on management to demonstrate cost control in the upcoming quarters. The neutral stance reflects the high uncertainty; the probability-weighted expected return is positive but skewed by a high-risk tail. The stance would upgrade to bullish on confirmation of margin stabilization in the next earnings report, likely manifested in a gross margin recovery above 13.5%. It would downgrade to bearish if the stock breaks below $200, signaling a failure of the recent relief rally and a likely retest of the lows.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $396.31 and implied upside of +30.0% versus the current price.
Average Target
$396.31
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$244 - $396
Analyst target range
A cohort of 13 analysts provides coverage, but the data provided lacks a consensus price target or recommendation breakdown, indicating high uncertainty and likely divergent views following the Q4 shock. The available data shows analysts are focused on forward estimates, with an average EPS forecast of $41.63 for an unspecified period, ranging from a low of $39.85 to a high of $44.55, and an average revenue estimate of $204.44 billion. The institutional ratings from February 2026 show a mixed but cautious picture, with actions including a downgrade from RBC Capital (from Outperform to Sector Perform), reiterations of Hold/Neutral/Equal Weight ratings from Barclays, Wells Fargo, Truist, TD Cowen, UBS, and Cantor Fitzgerald, and maintained Buy ratings from Jefferies and Guggenheim alongside a maintained Sell from Goldman Sachs. This pattern suggests the analyst community is largely in a 'wait-and-see' mode, with the recent CMS news potentially not yet fully reflected in revised targets. The wide range in EPS estimates and the lack of a published price target range signal high uncertainty regarding the company's near-term earnings power and the appropriate discount rate to apply, which is typical following a fundamental crisis. The limited and mixed signals from institutional ratings underscore that the investment case is highly contested, with the burden of proof on management to restore credibility.
Bulls vs Bears: HUM Investment Factors
The investment debate for Humana is a classic clash between deep-value valuation and severe fundamental impairment. The bull case, currently supported by stronger evidence due to the recent regulatory catalyst and extreme valuation discount, hinges on a credible and swift return to profitability. The bear case is grounded in the tangible, catastrophic collapse of margins and cash flow in Q4 2025. The single most important tension is the sustainability of the Q4 margin shock: if medical cost trends normalize and the CMS payment boost flows through, the stock's depressed multiple could expand dramatically. However, if Q4 proves indicative of a structural profitability problem rather than a one-time misstep, the deep-value trap will snap shut, and the stock could retest its lows.
Bullish
- Extreme Valuation Discount: Humana trades at a trailing PS ratio of 0.24, near the absolute bottom of its historical range (highs above 2.8). This deep-value multiple, coupled with an implied forward PS of ~0.15 based on $204.4B revenue estimates, prices in a worst-case scenario, leaving substantial room for multiple expansion on any profit recovery.
- Positive Regulatory Catalyst: The favorable 2027 Medicare Advantage payment update from CMS in early April 2026 provided a significant sector-wide reprieve, boosting revenue visibility. This news directly catalyzed the stock's 32% one-month surge from ~$183 to over $217, indicating a potential inflection point in regulatory sentiment.
- Strong Top-Line Growth: Q4 2025 revenue grew 11.3% YoY to $32.52B, demonstrating resilient demand for its core Medicare Advantage offerings. The company's revenue base is massive and expanding, with analyst consensus estimating $204.44B in forward revenue, providing a foundation for earnings recovery.
- Analyst EPS Confidence: Despite the Q4 shock, analysts project a significant earnings rebound with an average forward EPS estimate of $41.63, ranging from $39.85 to $44.55. This implies a forward P/E of ~5.6 based on the current price, suggesting the market deeply discounts these profit projections.
Bearish
- Catastrophic Profitability Collapse: Q4 2025 saw a net loss of -$796M (net margin -2.45%) and operating income of -$1.03B. Gross margin collapsed to 11.67% from 17.37% in Q1 2025, indicating severe and persistent medical cost pressure that may not be fully resolved by the CMS update.
- Severe Liquidity & Cash Burn: The Q4 loss triggered a cash flow crisis, with operating cash flow of -$1.65B and free cash flow of -$1.85B for the quarter. The current ratio of 0.72 indicates potential near-term liquidity constraints if the cash burn is not swiftly reversed.
- Deep Technical Damage: The stock remains down 8.75% over one year, underperforming the S&P 500 by ~38%, and trades at only 46% of its 52-week range. The maximum drawdown of -47.54% and a 52-week low of $163.11 establish a deep support level that could be retested if sentiment sours again.
- Analyst Uncertainty & Wait-and-See: Institutional ratings from February 2026 show a cautious mix of Holds, Neutral, and a few Buys alongside a maintained Sell (Goldman Sachs). The lack of a published consensus price target and the wide EPS estimate range signal high uncertainty and a lack of conviction in the recovery timeline.
HUM Technical Analysis
The stock is in a deep downtrend over the past year, with a 1-year price change of -8.75%, significantly underperforming the S&P 500's +29.04% gain. As of the latest close of $233.63, the price is trading at approximately 46% of its 52-week range (between $163.11 and $315.35), indicating it is still much closer to its lows than its highs, which suggests a stock that has been severely punished but may present a potential value opportunity if fundamentals stabilize. The 6-month price change of -16.02% and a maximum drawdown of -47.54% underscore the severity and persistence of the sell-off that began in late January 2026. Recent momentum, however, shows a powerful short-term reversal, with the stock up 32.03% over the past month and 19.69% over the past three months, significantly outpacing the S&P 500's gains of 9.98% and 4.14%, respectively. This divergence from the longer-term downtrend signals a potential trend reversal or a significant relief rally, likely catalyzed by the positive CMS payment news in early April, which saw the stock jump from around $183 to over $217 in a single session. Key technical levels are clearly defined, with major support at the 52-week low of $163.11 and formidable resistance at the 52-week high of $315.35. A sustained breakout above the recent recovery highs near $245 would signal strengthening bullish conviction, while a breakdown below the $163 support could indicate a resumption of the downtrend. The stock's beta of 0.445 indicates it has been significantly less volatile than the broader market during this turbulent period, which is unusual for a stock that experienced such a large drawdown and suggests its moves have been driven by idiosyncratic, fundamental shocks rather than broad market sentiment.
Beta
0.68
0.68x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$315
Price range past year
Annual Return
+33.2%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +53.8% | +8.2% |
| 3m | +70.5% | +9.0% |
| 6m | +28.6% | +10.5% |
| 1y | +33.2% | +26.5% |
| ytd | +15.3% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $32.52 billion representing an 11.3% year-over-year increase, though this masks a severe profitability crisis. The revenue trajectory shows consistent top-line expansion, primarily driven by the Insurance Segment, which contributed $31.34 billion in the latest period, versus $5.96 billion from the CenterWell Segment. However, profitability has collapsed dramatically; Q4 2025 saw a net income loss of -$796 million, translating to a net margin of -2.45%, a stark reversal from the profitable Q3 ($195 million net income) and Q2 ($545 million). Gross margin compressed to 11.67% in Q4 from 14.27% in Q3 and 17.37% in Q1 of 2025, indicating severe pressure on medical cost ratios. The operating margin turned deeply negative at -3.15% in Q4, compared to +0.33% in Q3. The balance sheet and cash flow position reveal significant stress stemming from the Q4 loss. The company generated negative free cash flow of -$1.85 billion in Q4 and negative operating cash flow of -$1.65 billion, severely depleting liquidity. For the trailing twelve months, free cash flow was a positive $375 million, but this is overshadowed by the quarterly hemorrhage. The debt-to-equity ratio stands at a manageable 0.73, and the current ratio is a weak 0.72, indicating potential liquidity constraints. Return on equity was 6.73% and return on assets was 3.64%, but these full-year figures are dragged down by the catastrophic Q4, highlighting the quarter's outsized impact on annual financial health.
Quarterly Revenue
$32.5B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$375000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given the company reported a net loss in the most recent quarter, we lead with the Price-to-Sales (PS) ratio as the primary valuation metric. Humana's trailing PS ratio is 0.24, which is exceptionally low and reflects the market's severe derating following the Q4 earnings disaster. The forward-looking valuation is not explicitly provided, but the market cap of $30.85 billion against estimated revenue of $204.44 billion implies a forward PS of approximately 0.15, suggesting the market expects significant revenue growth but remains skeptical of profit recovery. Comparing to industry averages is challenging without explicit sector PS data, but a sub-0.3 PS ratio is typically deep value territory for a large, established insurer, indicating a substantial discount likely due to perceived fundamental risk. Historically, Humana's own PS ratio has collapsed from levels above 1.0 throughout much of 2024 and early 2025 to the current 0.24. The current PS of 0.24 is near the absolute bottom of its observable historical range, which has seen highs above 2.8. This positioning suggests the stock is pricing in a worst-case scenario of sustained margin pressure and potentially impaired growth, leaving room for significant multiple expansion if the company can demonstrate a credible path back to profitability.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1073x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute and center on the company's ability to stem its cash burn and restore margins. The Q4 2025 net loss of -$796M caused operating cash flow to plunge to -$1.65B and free cash flow to -$1.85B, severely depleting liquidity as evidenced by a weak current ratio of 0.72. The gross margin compression from 17.37% in Q1 to 11.67% in Q4 indicates medical costs are running significantly above expectations, a risk that may persist despite the favorable CMS update. Furthermore, the company's heavy reliance on government-sponsored Medicare/Medicaid programs (nearly all medical membership) creates concentrated regulatory and reimbursement risk.
Market & Competitive Risks include the threat of permanent multiple compression. The stock's trailing PS ratio of 0.24 represents a severe derating from historical norms above 1.0, and a failure to recover profitability could cement this discount. Competitive intensity in the Medicare Advantage space remains high, pressuring pricing and member acquisition costs. The stock's low beta of 0.445 suggests its moves are idiosyncratic, driven by company-specific news like earnings and CMS updates, making it highly sensitive to any further fundamental disappointments. The recent sector-wide rally on CMS news also introduces the risk of a sentiment reversal if subsequent data points are less favorable.
Worst-Case Scenario involves a failure to contain medical costs in 2026, leading to another significant earnings miss and a breach of liquidity covenants. This could trigger a wave of analyst downgrades, a loss of member confidence, and forced asset sales. In this adverse scenario, the stock would likely retest and potentially break below its 52-week low of $163.11. A realistic downside from the current price of $233.63 to this level represents a loss of approximately -30%. A break below $163 could see a further decline toward the $150 level, representing a total drawdown of -36% from current levels, as the market prices in a more prolonged period of unprofitability and strategic uncertainty.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The inability to reverse the severe medical cost inflation that caused Q4 2025 gross margins to collapse to 11.67%, leading to sustained losses. 2) Liquidity & Financial Risk: The quarterly cash burn of -$1.85B in FCF and a weak current ratio of 0.72 could force unfavorable financing actions if not corrected. 3) Regulatory & Competitive Risk: Heavy reliance on government Medicare/Medicaid programs makes profits vulnerable to future payment rate changes and intense competition. 4) Sentiment & Technical Risk: The stock is still down 8.75% over the past year and could retest its 52-week low of $163.11 if the recovery narrative falters.
Our 12-month outlook presents three scenarios. The Base Case (50% probability) sees a range of $230-$270 as the company shows gradual margin improvement, aligning with a stabilization in analyst sentiment. The Bull Case (30% probability) targets $280-$315, requiring a swift profit recovery and multiple expansion. The Bear Case (20% probability) warns of a drop to $163-$200 if cost pressures persist, leading to another earnings disaster. The most likely outcome is the Base Case, predicated on the assumption that the Q4 shock was an extreme but correctable event, not a new normal. The key variable is the trajectory of medical costs in the next two quarterly reports.
HUM is deeply undervalued based on traditional sales and forward earnings multiples, but this discount is warranted by its recent fundamental crisis. The trailing PS ratio of 0.24 is near the bottom of its historical range and well below levels seen when the company was profitable. Based on analyst revenue estimates of $204.44B, the forward PS is approximately 0.15. The market is pricing in a scenario of permanently impaired margins. If the company can return to even modest profitability, the stock is significantly undervalued. The current valuation implies extreme skepticism, offering substantial upside if that skepticism is proven wrong.
HUM is a high-risk, high-potential-reward investment at its current level. For risk-tolerant, contrarian investors, it presents a compelling deep-value opportunity with a trailing PS ratio of 0.24 and analyst forward EPS estimates implying a P/E of ~5.6. The recent 32% rally on positive CMS news shows its sensitivity to catalysts. However, it is not a good buy for conservative investors, as it carries severe risks from its recent profitability collapse (Q4 net margin -2.45%) and liquidity strain (current ratio 0.72). A purchase should be conditioned on a belief that management can swiftly execute a cost turnaround.
HUM is unsuitable for short-term trading due to its high sensitivity to idiosyncratic news (earnings, CMS updates) and recent volatility (47.54% max drawdown). Its low beta of 0.445 also means it may not move with the broader market, reducing its appeal for tactical plays. It is best considered a long-term, event-driven turnaround investment with a minimum horizon of 18-24 months. This timeframe allows for the execution of cost-containment plans, the full benefit of the CMS payment update to materialize, and for the market to re-assess the sustainability of the recovery. The lack of a significant dividend (yield 1.39%) further supports a total-return, capital appreciation focus over the long term.